Clinical trials: Rhinosinusitis
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to…
- Trial name
- VIBRANT (NCT06164704)
- Testing
- Verekitug (UPB-101)
- Where
- 41 sites in United States, Czechia and 3 more
- Volunteers
- 81 people
- Sponsor
- Upstream Bio Inc.
Allergic Fungal Rhinosinusitis
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)
Primary Objective: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) Secondary Objectives: To evaluate the efficacy of treatment with…
- Trial name
- AIMS (NCT04684524)
- Testing
- Dupilumab SAR231893
- Where
- 47 sites in United States, Argentina and 7 more
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Mechanisms of Smell Improvement With Dupilumab.
This study seeks to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with chronic sinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT05964465
- Testing
- Dupilumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis
Dupilumab in CRSsNP
Primary Objective: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only Secondary Objectives: To evaluate the…
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder
- Trial name
- Liberty CRSsNP (NCT04678856)
- Testing
- Dupilumab SAR231893
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 71 people
- Sponsor
- Sanofi
Asthma, Aspirin-Induced, Chronic Rhinosinusitis With Nasal Polyps
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Primary objective: to investigate the efficacy of Mepolizumab 100 milligram (mg) every month compared to placebo in reducing validated Sinonasal Outcome Test -22 score and on reducing endoscopic Nasal Polyp Score.
- Trial name
- AirGOs-biol (NCT04823585)
- Testing
- Mepolizumab
- Where
- Finland
- Volunteers
- 95 people
- Sponsor
- Helsinki University Central Hospital
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
Multicenter, phase III, randomized, blinded, controlled, parallel group.
- Trial name
- NCT05295459
- Testing
- LYR-210, Background therapy
- Where
- 57 sites in United States, Belgium and 4 more
- Volunteers
- 182 people
- Sponsor
- Lyra Therapeutics
Chronic Rhinosinusitis With Nasal Polyps
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
- Trial name
- WAYPOINT (NCT04851964)
- Testing
- Experimental: Tezepelumab, Mometasone furoate or equivalent intranasal corticosteroid
- Where
- 112 sites in United States, Canada and 8 more
- Volunteers
- 416 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Chinese Adult Participants With CRSwNP
This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy…
- Trial name
- NCT05878093
- Testing
- Dupilumab, Budesonide
- Where
- 18 sites in China
- Volunteers
- 63 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
This was a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18 or older with CRSwNP that is not adequately…
- Trial name
- NCT05049122
- Testing
- Dupilumab SAR231893
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis
Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis
Chronic rhinosinusitis (CRS) affects up to 12.5% of the US population and has a significant disease burden. The recommended medical management of CRS includes large-volume, low-pressure saline lavage, systemic antibiotics, and…
- Conditions
- Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis
- Trial name
- NCT03705793
- Testing
- Mometasone Furoate Nasal Irrigation, Mometasone Nasal Spray
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Chronic Rhinosinusitis
Microcurrent Device (TIVIC Health)
The purpose of this study is to investigate whether daily use of a microcurrent neuromodulation device, which applies a small current of electricity to the forehead and maxillary region, will decrease the pain experienced by…
- Trial name
- NCT05198518
- Testing
- Microcurrent TENS device
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Allergic Fungal Rhinosinusitis
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS). Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in…
- Trial name
- ADAPT (NCT05545072)
- Testing
- Dupilumab, Intranasal Corticosteroid Sprays (INCS)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.
- Trial name
- ENLIGHTEN 1 (NCT05219968)
- Testing
- LYR-210, Background Therapy
- Where
- 55 sites in United States, Austria and 3 more
- Volunteers
- 196 people
- Sponsor
- Lyra Therapeutics
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.
- Trial name
- NCT05248997
- Testing
- rimegepant 75 mg ODT
- Where
- 33 sites in United States
- Volunteers
- 261 people
- Sponsor
- Pfizer
Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
N-acetylcysteine (NAC), known to have mucolytic and antioxidant effects, is widely used to treat respiratory diseases and manage post-surgery pulmonary complications.
- Conditions
- Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis, Chronic Rhinosinusitis
- Trial name
- NOTUS (NCT04131686)
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
This study will assess the safety, tolerability, pharmacokinetics and efficacy of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior functional endoscopic sinus surgery.
- Trial name
- NCT05035654
- Testing
- LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2)
- Where
- 25 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Lyra Therapeutics
Rhinosinusitis Chronic, Microbiome
Impact of Symbiofilm On Nasal Microbiota
Healsea® chronic is CE marked medical device indicated in adults for the treatment of nasal symptoms of chronic rhinosinusitis. This is an hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract (0.2%)…
- Trial name
- ISONAM (NCT05015530)
- Testing
- Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Lallemand Pharma AG
Common Cold
Testing the Efficacy in Adults With Cold of HEalsea Rescue*
Healsea® Rescue* is a CE-marked class I medical device. This is a saline-based nasal spray supplemented with a natural Symbiofilm™ extract (0.04%) isolated from the marine bacteria.
- Trial name
- TEACHER (NCT05819190)
- Testing
- Healsea Rescue*
- Where
- Bulgaria
- Volunteers
- 200 people
- Sponsor
- Lallemand Pharma AG